EQUITY RESEARCH – COMMISSIONED RESEARCH Research report prepared by DNB Markets, a division of DNB Bank ASA

Materials

Q2 results review

This report was completed and disseminated at CIRCULATIONT CET on CIRCULATIOND



cha

NEXAM CHEMICAL

No wind in its sales

Q2 sales were down 25% YOY, driven by lower volumes due to inventory reductions and overall weaker demand. Sales in Performance Chemical were affected by lower volumes from the wind-power industry and, while we expect a recovery during H2, it will likely take longer than we had expected. We have lowered our 2023e sales to SEK191m following the Q2 results, and our fair value to SEK8–10 (10–14).

Q2 review. Group sales declined by 25% YOY, while adj. EBITDA was SEK-5.5m (we expected SEK2.3m). According to the company, the weak top line was due to lower volumes in various customer segments, in which most reduced their inventory levels. At the same time, overall demand seems to have been restrained due to a more uncertain macroeconomic outlook. Primarily, sales in Performance Chemical were hit by lower volumes, declining c31% YOY to cSEK15.5m. Sales in Performance Masterbatch were SEK26.2m (down c21% YOY). On a positive note, the gross margin was solid at c42.7% (versus 42.2% in Q1 2023 and 39.5% in Q2 2022).

Performance Chemical. The negative growth in sales in Performance Chemical was driven by lower volumes from the wind power industry. According to the company, c1/3 of the Performance Chemical sales (i.e. cSEK5m) came from the wind power industry. To compare, sales from DIAB alone amounted to cSEK10m in Q1 2023. The company sees indications that customers are at the end phase of inventory adjustments, so volumes from the wind-power industry should increase in H2. However, this recovery will likely take longer than we previously expected. Several projects and products in Reactive Recycling seem to be progressing, but we do not expect this to be a growth driver in 2023.


Financial position. Nexam's cash position is cSEK20.4m, and it says it does not plan on raising further capital, but we believe the risk of a rights issue has increased following the weak quarterly results.

Estimates cut, and fair value reduced to SEK8–10. While the company expects the wind-power industry to accelerate during the autumn, we believe this could take longer than we previously expected. As a result, we have cut our 2023e sales to SEK191m and, in turn, our adj. EBITDA for 2023 to SEK-9m. Consequently, we have lowered our fair value to SEK8–10.

Year-end Dec	2019	2020	2021	2022	2023e	2024e	2025e
Revenue (SEKm)	130	166	219	222	191	254	345
EBITDA adj (SEKm)	-9	5	8	1	-9	22	46
EBIT adj (SEKm)	-19	-5	-3	-11	-23	8	27
PTP (SEKm)	-17	-8	-5	-13	-24	6	24
EPS rep (SEK)	-0.25	-0.14	-0.07	-0.15	-0.26	0.05	0.23
EPS adj (SEK)	-0.31	-0.11	-0.05	-0.15	-0.30	0.05	0.23
Revenue growth (%)	18.4	27.5	32.3	1.0	-13.8	32.9	35.8
EBIT growth adj (%)	nm	nm	nm	nm	nm	nm	233.8
EPS growth adj (%)	nm	nm	nm	nm	nm	nm	322.0
EBIT margin adj (%)	-14.9	-3.2	-1.4	-5.0	-11.9	3.2	7.9
EV/Sales adj (x)	4.33	4.07	3.71	1.92	1.56	1.17	0.86
EV/EBITDA adj (x)	nm	nm	nm	nm	nm	13.3	6.4
EV/EBIT adj (x)	nm	nm	nm	nm	nm	36.4	10.9
P/E adj (x)	nm	nm	nm	nm	nm	63.2	15.0
ROE (%)	nm	nm	nm	nm	nm	2.2	8.9
ROCE (%)	nm	nm	nm	nm	nm	3.8	12.1

Source: Company (historical figures), DNB Markets (estimates)

NEXAM versus OMXS30 (12m)



Source. Facisei

SUMMARY

Share price (SEK)	3.42
Tickers	NEXAM SS
CAPITAL STRUCTURE	
No. of shares (m)	80.9
No. of shares fully dil. (m)	80.9
Market cap. (SEKm)	277
NIBD adj end-2023e (SEKm)	21
Enterprise value adj (SEKm)	298
Net debt/EBITDA adj (x)	-2.34
Free float (%)	84

Source: Company, DNB Markets (estimates)

Note: Unless otherwise stated, the share prices in this note are the last closing price

NEXT EVENT

IAEVI EAEIAI	
Q3 2023	23/10/2023

ESTIMATE CHANGES (SEK)

Year-end Dec	2023e	2024e	2025e
Sales (old)	245.3	312.2	387.8
Sales (new)	191.2	254.1	345.0
Change (%)	-22.1	-18.6	-11.0
EPS adj (old)	-0.05	0.17	0.30
EPS adj (new)	-0.30	0.05	0.23
Change (%)	nm	-67.2	-23.6

Source: DNB Markets,

This report has been commissioned and paid for by the company, and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II


ANALYSTS

Hanna Lindbo

Please see the last two pages for important information. This research report was not produced in the US. Analysts employed by non-US affiliates are not registered/ qualified research analysts with FINRA in the United States.

Overview

Valuation (add listing currency here, e.g. SEK)



Valuation methodology

- Our fair value of SEK8–10 is based on speciality polymer peers' 2023e EV/sales and our DCF.
- The high end of our fair value is based on our peer group's 2023e EV/sales applied to our forecasts and DCF.
- The low end of our fair value is based on a 10% higher WACC of 14.4% in our base-case DCF.

Source: DNB Markets

Downside risks to our fair value

- A lack of growth in the Performance Chemicals segment could make the valuation look high.
- A cyclical downturn hitting Performance Masterbatch (accounting for c53% of sales in 2022), leading to the group missing its sales target.
- Long-term, substituting plastic bottles with bottles for life and plastic packaging with paper could be negative for Performance Masterbatch.

Source: DNB Markets

DNB Markets estimates

- We expect a 2022–2025 sales CAGR of 16%.
- We expect the initiated cost savings programme to contribute positively to earnings, but believe it will not be enough for the company to reach positive EBIT in 2023e.

Source: DNB Markets


Source: DNB Markets

Upside risks to our fair value ■ Higher than expected order intake in

- Higher than expected order intake in the High Performance segment.
- In our view, the recycling business offers the largest potential, and any evidence of market share gains could be a swing factor in the valuation.
- Better cost control could improve the margin profile and, in a mature state, we note that EBIT margins average 18% at specialty polymer peers.

Source: DNB Markets

Sales bridge 2022-2024e (SEKm)



Source: DNB Markets (forecasts), company (historical data)

ESG overview

Sustainability assessment

	Positive	Negative
Conclusions	■ Nexam Chemical's products are designed to improve resource efficiency and recyclability, restoring features of used polymers, which is both cost- and climate-effective. For example, wind turbines can be built out of PET foam (from recycled PET), improving sustainability.	■ We believe the Performance Masterbatch segment could face structural headwinds from increasing penetration of paper versus plastic in several applications such as bottles, packaging, etc., which could reduce the need for colour and additive masterbatches.
	■ Nexam Chemical's products allow clients to substitute heavier materials with polymers, reducing energy consumption and aiding the environment.	Despite contributing to higher plastic recyclability and resource-efficiency, there is a risk of a negative ESG perception, as Nexam Chemical's technology is designed to be used with plastics.
Actions being taken by company	■ Nexam Chemical's products are a crucial part of the wind-energy market, in our view, enhancing the performance of core materials, allowing for taller and larger rotor blades, and in turn improving efficiency.	Regulatory frameworks and directives could work against the use of plastics, while competing solutions could erode the scope for market share gains and opportunities for Nexam Chemical.
Key ESG drivers Short-term	■ Lightweighting in industries like aerospace and automotive is a key topic, and complex settings such as engines are one of the few areas where development has not moved forward over the past few years. For instance, incorporating Nexam Chemical's additives in the production of jet engines can result in a c30% weight-saving versus titanium. ■ According to BNEF, installed wind capacity is set	■ Changing consumer behaviour could affect the market drivers for the more mature Performance Masterbatch segment, e.g. slumping demand if the use of certain plastics (like single-use) is banned, and finding alternative products for substitution could limit growth.
	to increase significantly over the coming years. Given the move towards longer and larger rotor blades, we also expect demand for stronger core materials, and thus Nexam Chemical's products.	
Long-term	■ Governmental initiatives to increase the share of wind power in its energy mix could benefit Nexam long-term as it is well positioned in the PET-foam business.	Significant changes to regulations could render Nexam Chemical's technology and business model outdated or obsolete.
	■ Hybrid and electric vehicles contain more polymers and composite technologies than ICE+ and could offer a sizeable market for Nexam Chemical's	

Source: DNB Markets

products.

Summary of positives

Sustainability the core of the business case

Nexam Chemical's products enhance the properties and performance of polymer materials by, for instance, improving strength, recyclability, ductility, and temperature resistance. This allows manufacturers to substitute more expensive and heavier materials with polymers, resulting in lower operating expenses while increasing resource efficiency by using recycled polymers, and reducing energy consumption by lightweighting. This is a key topic in several industries such as wind power (Nexam Chemical's products make it possible to build taller and larger rotor blades, increasing efficiency and lowering the levelised cost of energy (LCOE) of wind energy).

Multiple uses and multiple benefits

Proof-of-concept in each focus area and evidence of customer demand

Orders from manufacturers have validated Nexam Chemical's decade-long R&D programme, as exemplified by the renewal of the delivery agreement with DIAB, one of the world's largest PET foam manufacturers. Nexam Chemical has announced orders in all of its focus areas, with PET foam in particular showing steady growth in volumes, demonstrating healthy demand. In June 2021, the first fibre and filament order were placed, and by 2023 Nexam's Reactive Recycling business has started to receive some orders, which we believe could act as a proof-of-concept order to attract more customers.

Healthy demand evident in announced orders

Long-standing customer relationships and patented know-how

It takes several years to develop a product and reach commercial sales. As proof of its success, Nexam Chemical has built long-standing relationships with large international polymer producers, converters, and recyclers. It is collaborating with some of the industry leaders in its focus areas, three of the four largest PET foam manufacturers, and other well-established brands in the sector. In addition, the company has 56 patents, in our view raising the barriers to entry and reinforcing its standing as a first-mover in its niches.

Client relationships, collaborations, and patents form the foundations of Nexam Chemical's strategy

Vast market potential

Given the broad applications for Nexam Chemical's products, quantifying the addressable market is challenging; however, we believe the potential is vast. We estimate Nexam Chemical's PET foam opportunity at cSEK500m based on the four largest PET foam manufacturers, of which Nexam Chemical is already collaborating with three. Moreover, we see great potential in its Reactive Recycling business. The level of recycling is expected to increase in the coming years, driven by governmental actions to reduce plastic waste. The EU targets recycled plastic to account for 50% of plastic packaging by 2025 (currently at 15%, according to Nexam Chemical), and even if the reduction of waste does not reach the targeted range, we believe the market will experience significant growth in the coming years.

The sheer number of applications for Nexam Chemical's products indicates scope for growth

Energy independence

Russia's invasion of Ukraine has driven energy prices to historically high levels, as Russia accounted for a large part of the energy supply in Europe. This has shown the major effects reliance on certain countries for energy supply can have. In turn, the importance of reducing reliance on certain countries has been put on the agenda, and several governments have already raised their targets for the exploration of domestic energy supply. Renewable energy has been highlighted as one key source when expanding the energy supply. Thus, we find the trend toward national energy independence to be positive for Nexam Chemical due to its exposure to wind power.

Summary of negatives

The key risks that could affect our fair value relate to a potential failure to capitalise on the underlying growth prospects and could include: 1) slower composite uptake in select focus areas than expected; 2) entry of large and well-resourced companies offering composite solutions in select applications; and 3) slower regulatory approvals than expected, significantly delaying volume growth.

Competitive landscape

While Nexam Chemical has 56 patents and has built long-standing customer relationships in its focus areas, the polymer industry is still highly competitive, driven by technological advances and shifting market trends. Any further intensification of competition could threaten Nexam Chemical's value offering. The entry of any large and well-resourced companies could hit the company's market-share trajectory hard. Nexam Chemical's products also face indirect competition from other materials, such as metals, while falling metal and oil prices could reduce the economic appeal of substituting metals with composite materials.

Technology advancements and shifting demand trends can influence the competitive landscape

Consolidated end-markets could limit customer base

The PET foam market is highly consolidated. Nexam Chemical has built close relationships with key participants; however, other market leaders could look for alternative solutions to prevent any information-sharing with competitors. While we believe Nexam Chemical's products are the most attractive in the market, failure to expand its customer base could limit the total market potential and/or delay growth.

Potential clients might be reluctant to work with a company that is already working with many of the sector leaders

Financing and future capital requirements and dilution risk

Nexam's cash position in Q2 was cSEK20m, and, given that the company still has not showed positive operating results, we see a risk for refinancing in the future.

Lack of sales in Performance Chemicals could hinder the growth story

We believe Nexam Chemical's growth story centres on Performance Chemicals. In the event sales in the segment do not materialise, we believe this would be far less appealing.

Worsening economic conditions

Demand in Performance Masterbatch (47% of 2022 group sales) generally tracks in line with overall economic activity, so is susceptible to weakening economic fundamentals. Our base case assumes Performance Chemicals offsets any deterioration in key indicators, given the structural growth drivers in its end-markets and market-share gains. However, we see a risk of a global recession slowing organic growth within the Performance Masterbatch segment, especially as the Performance Chemicals division has struggled with growth in recent quarters.

Time will tell if Performance Chemicals makes Nexam Chemical immune to recession

Company overview

Nexam Chemical is a speciality chemical company with a world-leading, unique technology to enhance the properties and performance of plastics and polymers based on a decade-long R&D programme. It has deep roots in the scientific community, such as NASA's space programme.

Figure 4: Sales by segment (2022)





Figure 5: Sales (LHS, SEKk) and growth (RHS, %)



Source: Company (historical data), DNB Markets (estimates)

Source: Company, DNB Markets (graph structuring)


The company has two divisions:

- Performance Chemicals (c47% of 2022 sales) includes enhancing products for PET foam and high performance, polyethylene applications as well as the recycling business portfolio Reactive Recycling. The Performance Chemicals segment increased its top line by 45% in 2021, and we believe this will be the primary growth driver at Nexam Chemical.
- Performance Masterbatch (c53% of 2022 sales) includes the former Plasticolor, and mainly targets the plastics industry in the Nordics and Eastern Europe. We view Performance Masterbatch as more mature than Performance Chemicals, and see it as acting as a cash generator.

Man-made polymers are found in everything from clothing to packaging, household goods, and coatings. Durability, flexibility, and low costs are key characteristics. Nexam Chemical has created additives that are incorporated in the production process to improve the end-products, making them more resource-efficient in terms of weight, temperature resistance, strength, durability, and recyclability. This allows customers to substitute heavier and often more expensive inputs, in turn reducing opex. They also enhance environmental credentials, allowing manufacturers to use recycled plastics by restoring and improving the plastic's original properties.

Polymers are (pretty much) everywhere and in (pretty much) everything

Figure 6: Nexam Chemical's products enhance polymer performance



Source: Company (underlying data), DNB Markets (data structuring)

Forecast changes – P&L

		New			Old			Change	
(SEKm)	2023e	2024e	2025e	2023e	2024e	2025e	2023e	2024e	2025e
Revenues	191	254	345	245	312	388	-54	-58	-43
Cost of sales	-110	-140	-190	-141	-172	-213	32	32	24
Gross profit	83	114	155	105	141	175	-23	-26	-19
Operating expenses	-92	-92	-109	-93	-103	-118	1	11	9
EBITDA	-9	22	46	12	37	56	-22	-15	-10
EBITDA adj	-9	22	46	12	37	56	-22	-15	-10
EBITDA margin (%)	nm	8.8	13.4	5.1	12.0	14.5	nm	-3.1	-1.1
Depreciation	-14	-14	-19	-14	-17	-21	0	3	2
		_		_					_
EBIT	-23	8	27	-2	20	35	-21	-12	-8
EBIT adj	-23	8	27	-2	20	35	-21	-12	-8
Not interest	4	0	2	0	2	4	4	4	4
Net interest Net financial items	-1 -1	-2 -2	-3 -3	-2 -2	-3 -3	-4 -4	1	1 1	1
	-				_		1	-12	1 -7
PBT	-24	6	24	-4	17	31	-20	-12	-/
Taxes	0	-1	-6	0	-4	-7	0	3	2
Net profit	-24	4	18	-4	13	24	-20	-9	-6
Adjustments to net profit	0	0	0	0	0	0	0	0	0
Net profit adj	-24	4	18	-4	13	24	-20	-9	-6
rtot pront daj		·	10				20	Ü	· ·
Per share data (SEK)									
EPS	-0.26	0.05	0.23	-0.04	0.17	0.30	-0.22	-0.11	-0.07
EPS adj	-0.30	0.05	0.23	-0.05	0.17	0.30	-0.25	-0.11	-0.07
•									
Other key metrics (%)									
Revenue growth	-13.8	32.9	35.8	10.6	27.2	24.2	-24.4	5.6	11.5
EBIT adj growth	nm	nm	233.8	-84.3	-1269.6	71.8	nm	nm	162.0
EPS adj growth	nm	nm	322.0	-66.3	-431.3	80.9	nm	nm	241.2
Avg. number of shares (m)	81	81	81	81	81	81	0	0	0
Capex	-7	-12	-16	-8	-15	-19	1	3	3
OpFCF	-16	11	30	4	22	37	-20	-12	-7
NIBD adj	21	21	20	20	10	1	1	11	19

Source: DNB Markets

Forecast changes – By segment and assumptions

		New			Old			Change	
(SEKm)	2023e	2024e	2025e	2023e	2024e	2025e	2023e	2024e	2025e
Revenue									
Performance Masterbatch	110	114	120	120	126	133	-11	-12	-13
Performance Chemicals	82	140	225	125	186	255	-43	-46	-30
Assumptions									
Revenue org. % YOY	-14.50	32.84	35.77	9.91	27.21	24.22	-24.41	5.63	11.55
Structure impact % YOY	0.00	0.00	0.00		0.00	0.00		0.00	0.00
Currency impact % YOY	0.73	0.06	0.00	0.73	0.04	0.00	0.00	0.01	0.00

Source: DNB Markets

Quarterly numbers

(SEKm)	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023e	Q4 2023e	Q1 2024e	Q2 2024e	Q3 2024e
Revenues	54	55	57	56	52	42	46	51	59	60	65
Cost of sales	-32	-34	-35	-34	-30	-24	-26	-29	-33	-33	-36
Gross profit	21	22	22	21	22	18	20	23	27	27	29
Operating expenses	-21	-23	-21	-23	-22	-26	-21	-22	-23	-22	-23
EBITDA	2	-1	1	-1	0	-8	-1	0	4		6
Depreciation	-3	-3	-3	-3	-4	-4	-3	-3	-4	-3	-4
EBIT	-1	-4	-2	-4	-4	-12	-4	-3	0	2	3
Net interest	0	0	0	0	0	0	0	0	-1	-1	-1
Net financial items	0	0	0	0	0	0	0	0	-1	-1	-1
PBT	-2	-4	-2	-4	-4	-12	-5	-3	0	1	2
Taxes	0	0	0	0	0	0	0	0	0	0	0
Net profit	-2	-4	-2	-5	-4	-12	-5	-3	0	1	2
Adjustments to net profit	0	0	0	1	0	0	0	0	0	0	0
Net profit adj	-2	-4	-2	-4	-4	-12	-5	-3	0	1	2
Avg. number of shares (m)	81	81	81	81	81	81	81	81	81	81	81
Per share data (SEK)											
EPS	-0.02	-0.05	-0.05	-0.03	-0.04	-0.16	-0.06	-0.04	0.00	0.01	0.02
EPS adj	-0.02	-0.05	-0.03	-0.05	-0.05	-0.15	-0.06	-0.04	0.00	0.01	0.02
Growth and margins (%)											
Revenues, QOQ growth	-5.5	2.8	2.3	-1.8	-6.2	-20.3	10.5	11.6	15.7	0.8	7.7
Revenues, YOY growth	2.7	-7.1	12.9	-2.4	-3.1	-24.9	-18.9	-7.8	13.8	44.0	40.4
EPS adj, YOY growth	nm	nm	nm	nm	nm						
Gross margin	39.8	39.5	38.6	38.5	42.2	42.7	42.6	43.3	45.0	45.0	45.0
EBITDA adj margin	3.1	nm	1.3	nm	0.2	nm	nm	0.4	6.4	8.3	9.5
Depreciation/revenues	-5.3	-5.8	-5.1	-5.4	-7.3	-8.7	-7.0	-6.0	-6.0	-5.5	-5.5
EBIT adj margin	-2.2	-7.5	-3.8	-6.6	-7.1	-28.7	-9.3	-5.6	0.4	2.8	4.0
Net profit margin	nm	nm	nm	nm	nm						

Source: Company (historical figures), DNB Markets (estimates)

Adjustments to quarterly numbers

(SEKm)	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023e	Q4 2023e	Q1 2024e	Q2 2024e	Q3 2024e
EBITDA	2	-1	1	-1	0	-8	-1	0	4	5	6
Gains and losses	0	0	0	0	0	0	0	0	0	0	0
EBITDA adj	2	-1	1	-1	0	-8	-1	0	4	5	6
Gains and losses	0	0	0	0	0	0	0	0	0	0	0
EBIT	-1	-4	-2	-4	-4	-12	-4	-3	0	2	3
Gains and losses	0	0	0	0	0	0	0	0	0	0	0
EBIT adj	-1	-4	-2	-4	-4	-12	-4	-3	0	2	3
Net profit	-2	-4	-2	-5	-4	-12	-5	-3	0	1	2
Gains and losses	0	0	0	0	0	0	0	0	0	0	0
Net profit adj	-2	-4	-2	-4	-4	-12	-5	-3	0	1	2

Quarterly numbers by segment and assumptions

(SEKm)	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023e	Q4 2023e	Q1 2024e	Q2 2024e	Q3 2024e
Revenue											
Performance Masterbatch	30	33	29	25	30	26	27	26	31	27	28
Performance Chemicals	24	22	28	30	22	15	19	25	29	32	36
Assumptions											
Revenue org. % YOY	1.99	-7.59	12.31	-3.27	-3.81	-25.82	-19.68	-8.30	13.60	43.99	40.36
Structure impact % YOY	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Currency impact % YOY	0.69	0.48	0.61	0.91	0.70	0.93	0.78	0.49	0.21	0.00	0.00

Source: Company (historical figures), DNB Markets (estimates)

Annual P&L

(SEKm)	2016	2017	2018	2019	2020	2021	2022	2023e	2024e	2025e
Revenues	8	19	110	130	166	219	222	191	254	345
Cost of sales	-5	-12	-68	-82	-95	-135	-135	-110	-140	-190
Gross profit	5	9	47	54	71	85	88	83	114	155
Operating expenses	-24	-29	-53	-59	-66	-79	-88	-92	-92	-109
EBITDA	-24 -19	-29 -20	-55 -6		-00 5	- <i>1</i> 9	0	-92 -9	22	46
EDITUA	-19	-20	-6	-6	5	0	U	-9	22	40
Depreciation	-2	-3	-10	-10	-10	-11	-12	-14	-14	-19
EBIT	-22	-23	-16	-15	-5	-4	-12	-23	8	27
Net interest	0	0	-1	-2	-2	-1	-1	-1	-2	-3
Net financial items	0	0	-1	-2	-2	-1	-1	-1	-2	-3
PBT	-22	-23	-17	-17	-8	-5	-13	-24	6	24
Taxes	0	17	0	0	0	0	0	0	-1	-6
Effective tax rate (%)	0	75	-1	0	-7	-3	0	0	23	23
Net profit	-22	-6	-17	-17	-8	-5	-13	-24	4	18
Adjustments to net profit	0	-1	-3	-4	0	1	1	0	0	0
Net profit adj	-22	-7	-20	-21	-8	-4	-12	-24	4	18
. ,										
Avg. number of shares	62	65	68	68	73	80	81	81	81	81
Per share data (SEK)										
EPS	-0.36	-0.09	-0.25	-0.25	-0.14	-0.07	-0.15	-0.26	0.05	0.23
EPS adj	-0.36	-0.11	-0.30	-0.31	-0.11	-0.05	-0.15	-0.30	0.05	0.23
Growth and margins (%)										
Revenue growth	5.4	126.1	487.5	18.4	27.5	32.3	1.0	-13.8	32.9	35.8
EPS adj growth	nm	nm	nm	nm	nm	nm	nm	nm	nm	322.0
, 3										
Gross margin	43.4	37.4	38.1	36.7	42.8	38.5	39.1	42.7	45.0	45.0
EBITDA margin	nm	nm	nm	nm	3.0	2.9	0.1	nm	8.8	13.4
EBITDA adj margin	nm	nm	nm	nm	3.0	3.5	0.4	nm	8.8	13.4
Depreciation/revenues	-29.5	-15.9	-9.0	-7.6	-6.1	-4.8	-5.4	-7.2	-5.6	-5.5
EBIT margin	nm	nm	nm	nm	nm	nm	nm	nm	3.2	7.9
EBIT adj margin	-268.0	-129.3	-16.9	-14.9	-3.2	-1.4	-5.0	-11.9	3.2	7.9
PBT margin	nm	nm	nm	nm	nm	nm	nm	nm	2.2	7.0
Net profit margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm

Adjustments to annual P&L

(SEKm)	2016	2017	2018	2019	2020	2021	2022	2023e	2024e	2025e
EBITDA	-19	-20	-6	-6	5	6	0	-9	22	46
Gains and losses	-1	-2	-5	-6	0	0	-1	-1	0	0
EBITDA adj	-20	-21	-9	-9	5	8	1	-9	22	46
Gains and losses	-1	-2	-5	-6	0	0	-1	-1	0	0
EBIT	-22	-23	-16	-15	-5	-4	-12	-23	8	27
Gains and losses	-1	-2	-5	-6	0	0	-1	-1	0	0
EBIT adj	-22	-24	-19	-19	-5	-3	-11	-23	8	27
Net profit	-22	-6	-17	-17	-8	-5	-13	-24	4	18
Gains and losses	-1	-2	-5	-6	0	0	-1	-1	0	0
Net profit adj	-22	-7	-20	-21	-8	-4	-12	-24	4	18
Per share data (SEK)										
EPS	-0.36	-0.09	-0.25	-0.25	-0.14	-0.07	-0.15	-0.26	0.05	0.23
Recommended adjustment	0.00	-0.02	-0.05	-0.06	0.03	0.02	0.00	-0.04	0.00	0.00
EPS adj	-0.36	-0.11	-0.30	-0.31	-0.11	-0.05	-0.15	-0.30	0.05	0.23

Source: Company (historical figures), DNB Markets (estimates)

Cash flow

(SEKm)	2016	2017	2018	2019	2020	2021	2022	2023e	2024e	2025e
Net profit	-22	-6	-17	-17	-8	-5	-13	-24	4	18
Depreciation and amortisation	2	3	10	10	10	11	12	14	14	19
Other non-cash adjustments	0	0	-1	-2	-2	0	0	-1	-4	-9
Change in net working capital	2	1	-6	-14	-19	2	-11	15	-7	-21
Cash flow from operations (CFO)	-18	-18	-13	-21	-17	7	-11	5	12	17
Capital expenditure	-2	-84	-6	-11	-7	-6	-33	-7	-12	-16
Cash flow from investing (CFI)	-2	-84	-6	-11	-7	-6	-33	-7	-12	-16
Free cash flow (FCF)	-20	-102	-18	-32	-23	2	-44	-3	0	1
Net change in debt	117	55	-14	1	30	32	4	-6	-4	-4
Cash flow from financing (CFF)	117	55	-14	1	30	32	4	-6	-4	-4
Total cash flow (CFO+CFI+CFF)	97	-47	-33	-31	7	34	-40	-9	-4	-3
FCFF calculation										
Free cash flow	-20	-102	-18	-32	-23	2	-44	-3	0	1
Less: net interest	0	0	1	2	2	1	1	1	2	3
Less: tax shields/other	0	0	0	0	0	0	0	0	0	0
Growth (%)										
CFO	24.1	-5.0	30.2	-65.1	20.8	143.1	-253.0	141.0	162.3	38.8
CFI	16.6	-3923.3	93.4	-89.7	37.2	16.5	-500.7	78.6	-66.3	-36.0
FCF	23.4	-418.9	81.9	-72.5	26.2	107.4	-2640.0	94.2	105.3	277.7
CFF	19874.1	-52.6	-125.9	105.6	3666.3	7.9	-88.1	-255.8	33.3	0.0
FCFF	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm

Balance sheet

(SEKm)	2016	2017	2018	2019	2020	2021	2022	2023e	2024e	2025e
Assets	174	282	248	228	250	284	278	252	261	284
Inventories	6	15	19	25	32	32	35	31	38	52
Trade receivables	2	15	16	25 19	32 32	38	46	38	36 46	62
Other receivables	3	5	3	5	6	4	6	5	5	5
Cash and cash equivalents	133	86	54	23	30	64	23	15	11	8
Current assets	143	1 21	92	72	100	138	110	89	100	126
Property, plant and equipment	9	50	48	49	45	44	66	63	61	58
Goodwill	19	111	108	106	105	103	102	101	101	100
Non-current financial assets	3	0	0	0	0	0	0	0	0	0
Non-current assets	30	161	156	156	150	147	168	164	161	158
Total assets	174	282	248	228	250	284	278	252	261	284
Equity and liabilities	174	282	248	228	250	284	278	252	261	284
Total equity	164	188	171	155	187	228	216	195	199	217
Trade payables	1	14	14	12	14	17	20	17	25	35
Other payables and accruals	5	11	11	7	8	11	10	14	14	14
Short-term debt	1	13	13	14	13	13	6	3	3	3
Total current liabilities	7	38	39	33	36	42	36	34	42	51
Long-term debt	1	50	37	35	23	11	23	21	17	13
Pension liabilities	0	0	0	0	0	0	0	0	0	0
Other non-current liabilities	1	5	1	4	5	3	3	2	2	2
Total non-current liabilities	2	56	39	40	27	15	26	24	20	16
Total liabilities	10	94	77	73	63	56	62	58	62	67
Total equity and liabilities	174	282	248	228	250	284	278	252	261	284
Key metrics										
Net interest bearing debt	-131	-31	-15	17	-2	-36	16	21	21	20

Valuation ratios

(SEKm)	2016	2017	2018	2019	2020	2021	2022	2023e	2024e	2025e
Enterprise value										
Share price (SEK)	12.25	9.55	9.30	8.10	9.26	10.65	5.06	3.42	3.42	3.42
Number of shares (m)	62.11	64.85	67.52	67.52	73.06	79.91	80.92	80.92	80.92	80.92
Market capitalisation	761	619	628	547	677	851	409	277	277	277
Net interest bearing debt	-131	-31	-15	17	-2	-36	16	21	21	20
Adjustments to NIBD	0	0	0	0	0	0	0	0	0	0
Net interest bearing debt adj	-131	-31	-15	17	-2	-36	16	21	21	20
EV	630	589	613	563	674	815	425	298	298	297
EV adj	630	589	613	563	674	815	425	298	298	297
Valuation										
EPS	-0.36	-0.09	-0.25	-0.25	-0.14	-0.07	-0.15	-0.26	0.05	0.23
EPS adj	-0.36	-0.11	-0.30	-0.31	-0.11	-0.05	-0.15	-0.30	0.05	0.23
P/E	-34.0	-106.1	-37.2	-32.4	-66.1	-155.0	-33.3	-13.1	63.2	15.0
P/E adj	-34.1	-88.5	-31.4	-26.1	-83.6	-205.0	-34.2	-11.5	63.2	15.0
Average ROE	-19.2%	-3.3%	-9.6%	-10.5%	-4.7%	-2.6%	-5.7%	-11.8%	2.2%	8.9%
Earnings yield adj	-2.9%	-0.9%	-2.7%	-3.1%	-1.5%	-0.6%	-3.0%	-7.6%	1.6%	6.7%
EV/SALES	76.19	31.49	5.58	4.33	4.07	3.71	1.92	1.56	1.17	0.86
EV/SALES adj	76.19	31.49	5.58	4.33	4.07	3.71	1.92	1.56	1.17	0.86
EV/EBITDA	-32.3	-29.5	-106.4	-101.1	137.3	129.4	3797.4	-33.0	13.3	6.4
EV/EBITDA adj	-31.9	-27.8	-71.2	-59.4	137.3	107.3	502.7	-33.0	13.3	6.4
EV/EBIT	-28.7	-25.7	-39.1	-36.6	-127.7	-190.6	-35.8	-13.1	36.4	10.9
EV/EBIT adj	-28.4	-24.4	-33.1	-29.2	-127.6	-273.6	-38.1	-13.1	36.4	10.9
EV/capital employed	3.8	2.4	2.9	2.9	3.1	3.4	1.8	1.4	1.4	1.3
EV/OpFCF (taxed)	-37.5	-7.3	-56.3	-36.6	-517.8	508.5	-17.1	-24.0	36.3	12.8

Key accounting ratios

	2016	2017	2018	2019	2020	2021	2022	2023e	2024e	2025e
Profitability (%)										
ROA	-17.8	-2.5	-6.5	-7.2	-3.4	-2.0	-4.5	-9.1	1.7	6.8
ROCE	-18.8	-11.8	-8.2	-9.6	-2.6	-1.3	-4.6	-9.9	3.8	12.1
Return on invested capital (%)										
Net PPE/revenues	105.3	268.4	43.5	37.8	27.1	19.9	29.8	32.8	23.8	16.8
Cash flow ratios (%)										
FCF/revenues	-237.8	-545.8	-16.8	-24.4	-14.1	0.8	-19.9	-1.3	0.1	0.1
FCF yield (%)	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
CFO/revenues	-212.7	-98.8	-11.7	-16.4	-10.2	3.3	-5.0	2.4	4.7	4.8
CFO/market capitalisation	-2.3	-3.0	-2.1	-3.9	-2.5	0.9	-2.7	1.6	4.3	6.0
CFO/capex	-846.7	-22.1	-232.7	-202.5	-255.3	131.6	-33.5	64.1	101.1	103.2
CFO/current liabilities	-237.5	-48.0	-33.4	-63.6	-47.2	17.5	-30.6	13.3	28.2	32.2
Cash conversion ratio	89.0	1775.1	107.2	186.2	289.9	-32.0	348.1	10.5	3.1	2.8
Capex/revenues	25.1	447.0	5.0	8.1	4.0	2.5	14.9	3.7	4.6	4.6
Capex/depreciation	85.2	2817.4	55.8	106.8	64.8	52.2	275.8	51.6	82.6	84.5
OpFCF margin	-263.7	-560.4	-12.9	-15.4	-1.0	0.9	-14.6	-8.4	4.2	8.8
Leverage and solvency (x)										
Interest cover	nm	nm	-11.49	-9.43	-2.06	-3.58	-7.72	-19.50	3.80	9.69
EBIT/interest payable	nm	nm	nm	nm	nm	nm	nm	nm	4.02	9.88
Cash coverage	-120.28	-179.78	-4.29	-3.47	2.13	6.11	0.14	-6.78	9.02	14.08
Net debt/EBITDA	6.72	1.53	2.62	-2.96	-0.48	-5.76	141.73	-2.34	0.93	0.44
Total debt/total capital (BV)	0.01	0.23	0.20	0.22	0.14	0.09	0.10	0.09	0.07	0.05
LTD / (LTD + equity (MV))	0.00	80.0	0.06	0.06	0.03	0.01	0.05	0.07	0.06	0.04
Cash conversion cycle										
Inventory turnover days	465.8	460.9	104.4	110.4	124.8	87.4	93.3	101.9	99.5	99.5
Receivables turnover days	193.3	384.6	62.6	68.2	83.9	69.5	86.4	82.2	72.4	70.6
Credit period	98.4	448.8	77.8	53.6	54.5	46.4	53.7	57.6	66.4	66.4
Cash conversion cycle	560.7	396.8	89.1	124.9	154.3	110.5	126.0	126.5	105.5	103.8

14 July 2023

Important Information

Company: Nexam Chemical Coverage by Analyst: Hanna Lindbo Date: 14/07/2023

This report has been prepared by DNB Markets, a division of DNB Bank ASA. DNB Bank ASA is a part of the DNB Group. This report is based on information obtained from public sources that DNB Markets believes to be reliable but which DNB Markets has not independently verified, and DNB Markets makes no guarantee, representation or warranty as to its accuracy or completeness. This report does not, and does not attempt to, contain everything material which there is to be said about the Company. Any opinions expressed herein reflect DNB Markets' judgement at the time the report was prepared and are subject to change without notice. The report is planned updated minimum every quarter.

Any use of non-DNB logos in this report is solely for the purpose of assisting in identifying the relevant issuer. DNB is not affiliated with any such issuer.

This report is for clients only, and not for publication, and has been prepared for information purposes only by DNB Markets, a division of DNB Bank ASA.

This report is the property of DNB Markets. DNB Markets retains all intellectual property rights (including, but not limited to, copyright) relating to the report. Sell-side investment firms are not allowed any commercial use (including, but not limited to, reproduction and redistribution) of the report contents, either partially or in full, without DNB Markets' explicit and prior written consent. However, buy-side investment firms may use the report when making investment decisions, and may also base investment advice given to clients on the report. Such use is dependent on the buy-side investment firm citing DNB Markets as the source.

Risk warning - generally high risk

The risk of investing in financial instruments is generally high. Past performance is not a reliable indicator of future performance, and estimates of future performance are based on assumptions that may not be realised. When investing in financial instruments, the value of the investment may increase or decrease, and the investor may lose all or part of their investment. Careful consideration of possible financial distress should be made before investing in any financial instrument.

Conflict of interest

This report has been commissioned and paid for by the company, and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II.

Readers should assume that DNB Markets may currently or may in the coming three months and beyond be providing or seeking to provide confidential investment banking services or other services to the company, and may receive compensation for these services.

Share positions in the company:	Analyst*	Employees**	DNB***
Number of shares	0	433144	0

^{*}The analyst or any close associates. **Share positions include people involved in the production of credit and equity research, including people that could reasonably be expected to have access to it before distribution.

Recommendation distribution and corporate clients for the last 12 months

	Buy	Hold	Sell	No_rec	Total
Number	216	71	20	37	344
% of total	63%	21%	6%	11%	
DNB Markets client	31%	6%	2%	3%	143

^{***}Share positions as part of DNB Group. Holdings as part of DNB Markets investment services activity are not included.

14 July 2023

Legal statement

This Report is a research report within the meaning of Regulation (EU) NO 596/2014 on market abuse (Market Abuse Regulation), and has been prepared in accordance with rules set out in relevant industry standards issued by The Norwegian Securities Dealers Association. This Report has been prepared as general information and is therefore not intended as a personal recommendation of particular financial instruments or strategies, and does not constitute personal investment advice as defined the Norwegian securities trading act (Norwegian verdipapirhandelloven).

The analyst hereby certifies that (i) the views expressed in this report accurately reflect that research analyst's personal views about the company and the securities that are the subject of this report, and (ii) no part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in this report. DNB Markets employees, including research analysts, may receive compensation that is generated by overall firm profitability. Confidentiality rules and internal rules restricting the exchange of information between different parts of DNB Markets/DNB Bank ASA or the DNB Group are in place to prevent employees of DNB Markets who are preparing this report from utilizing or being aware of information available in the DNB Group that may be relevant to the recipients' decisions. DNB Markets and the DNB Group have incorporated internal rules and regulations in order to avoid any potential conflicts of interest.

The Report has been prepared by DNB Markets, a division of DNB Bank ASA, a Norwegian bank organized under the laws of the Kingdom of Norway and under supervision by the Norwegian Financial Supervisory Authority, The Monetary Authority of Singapore, and on a limited basis by the Financial Conduct Authority and the Prudential Regulation Authority of the UK, and the Financial Supervisory Authority of Sweden. Details about the extent of our regulation by local authorities outside Norway are available from us on request.

It is issued subject to the General Business Terms for DNB Markets and information about the terms is available at www.dnb.no. For requests regarding the General Business Terms of the Singapore Branch of DNB Bank ASA, please contact +65 6212 6144. Information about the DNB Group can be found at www.dnb.no. DNB Markets is a member of The Norwegian Securities Dealers Association, which has issued recommendations and market standards for securities companies. The Association's Internet address where the recommendations and market standards can be found is: www.vpff.no. This report is not an offer to buy or sell any security or other financial instrument or to participate in any investment strategy. No liability whatsoever is accepted for any direct or indirect (including consequential) loss or expense arising from the use of this report. Distribution of research reports is in certain jurisdictions restricted by law. Persons in possession of this report should seek further guidance regarding such restrictions before distributing this report. Please contact DNB Markets at 08940 (+47 915 08940) for further information and inquiries regarding this report.

Additional information for clients in Singapore

The report has been distributed by the Singapore Branch of DNB Bank ASA. It is intended for general circulation and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. You should seek advice from a financial adviser regarding the suitability of any product referred to in the report, taking into account your specific financial objectives, financial situation or particular needs before making a commitment to purchase any such product. You have received a copy of the report because you have been classified either as an accredited investor, an expert investor or as an institutional investor, as these terms have been defined under Singapore's Financial Advisers Act (Cap. 110) ("FAA") and/or the Financial Advisers Regulations ("FAR"). The Singapore Branch of DNB Bank ASA is a financial adviser exempt from licensing under the FAA but is otherwise subject to the legal requirements of the FAA and of the FAA. By virtue of your status as an accredited investor or as an expert investor, the Singapore Branch of DNB Bank ASA is, in respect of certain of its dealings with you or services rendered to you, exemple from having to comply with certain regulatory requirements of the FAA and FAR, including without limitation, sections 25, 27 and 36 of the FAA. Section 25 of the FAA requires a financial adviser to disclose material information concerning designated investment products which are recommended by the financial adviser to you as the client. Section 27 of the FAA requires a financial adviser to have a reasonable basis for making investment recommendations to you as the client. Section 36 of the FAA requires a financial adviser to include, within any circular or written communications in which he makes recommendations concerning securities, a statement of the nature of any interest which the financial adviser (and any person connected or associated with the financial adviser) might have in the securities. Please contact the Singapore branch of DNB Bank ASA at +65 6212 6144 in respect of any matters arising from, or in connection with, the report. The report is intended for and is to be circulated only to persons who are classified as an accredited investor, an expert investor or an institutional investor. If you are not an accredited investor, an expert investor or an institutional investor, please contact the Singapore Branch of DNB Bank ASA at +65 6212 6144. We, the DNB group, our associates, officers and/or employees may have interests in any products referred to in the report by acting in various roles including as distributor, holder of principal positions, adviser or lender. We, the DNB group, our associates, officers and/or employees may receive fees, brokerage or commissions for acting in those capacities. In addition, we, the DNB group, our associates, officers and/or employees may buy or sell products as principal or agent and may effect transactions which are not consistent with the information set out in the report.

In the United States

Each research analyst named on the front page of this research report, or at the beginning of any subsection hereof, hereby certifies that (i) the views expressed in this report accurately reflect that research analyst's personal views about the company and the securities that are the subject of this report; and (ii) no part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in this report

The research analyst(s) named on this report are foreign research analysts as defined by FINRA Rule 1050. The only affiliate contributing to this research report is DNB Bank through its DNB Markets division ("DNB Markets/DNB Bank"); the foreign research analysts employed by DNB Markets/DNB Bank are named on the first page; the foreign research analysts are not registered/qualified as research analysts with FINRA; foreign research analysts are not associated persons of DNB Markets, Inc. and therefore are not subject to the restrictions set forth in FINRA Rules 2241 and 2242 regarding restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

This is a Third Party Research Report as defined by FINRA Rules 2241 and 2242. Any material conflict of interest that can reasonably be expected to have influenced the choice of DNB Markets/DNB Bank as a research provider or the subject company of a DNB Markets/DNB Bank research report, including the disclosures required by FINRA Rules 2241 and 2242 can be found above.

This report is being furnished solely to Major U.S. Institutional Investors within the meaning of Rule 15a-6 under the U.S. Securities Exchange Act of 1934 and to such other U.S. Institutional Investors as DNB Markets, Inc. may determine. Distribution to non-Major U.S. Institutional Investors will be made only by DNB Markets, Inc., a separately incorporated subsidiary of DNB Bank that is a U.S. broker-dealer and a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

Any U.S. recipient of this report seeking to obtain additional information or to effect any transaction in any security discussed herein or any related instrument or investment should contact DNB Markets, Inc., 30 Hudson Yards, 81st Floor, New York, NY 10001, telephone number +1 212-551-9800.

In Canada

The Information has been distributed in reliance on the International Dealer Exemption pursuant to NI 31-103 section 8.18. Please be advised that:

1) DNB Bank ASA (DNB Markets) and DNB Markets, Inc. are not registered as a dealer in the local jurisdiction to make the trade. We provide our services in Canada as an exempt international dealer. 2) The jurisdiction of DNB Bank ASA (DNB Markets) and DNB Markets, Inc.'s head office is Norway. 3) There may be difficulty enforcing legal rights against DNB Bank ASA (DNB Markets) and DNB Markets, Inc. because all or substantially all of their assets may be situated outside of Canada. 4) The name and address of the agent for service of process for DNB Bank ASA (DNB Markets) and DNB Markets, Inc. in the local jurisdiction is: Alberta: Blake, Cassels & Graydon LLP, 855 - 2nd Street S.W., Suite 3500, Bankers Hall East Tower, Calgary, AB T2P 4J8. British Columbia: Blakes Vancouver Services Inc., 595 Burrard Street, P.O. Box 49314, Suite 2600, Three Bentall Centre, Vancouver, BC V7X 1L3. Manitoba: MLT Aikins, 30th Floor, Commodity Exchange Tower, 360 Main Street, Winnipeg, MB R3C 4G1. New Brunswick: Stewart McKelvey, Suite 1000, Brunswick House, 44 Chipman Hill, PO Box 7289, Station A, Saint John, NB E2L 2A9. Newfoundland and Labrador: Stewart McKelvey, Suite 1100, Cabot Place, 100 New Gower Street, P.O. Box 5038, St. John's, NL A1C 5V3. Nova Scotia: Stewart McKelvey, Purdy's Wharf Tower One, 1959 Upper Water Street, Suite 900, P.O. Box 997, Halifax, NS B3J 2X2.

Northwest Territories: Field LLP, 601, 4920 52nd Street, Yellowknife, NT X1A 3T1. Nunavut: Field LLP, P.O. Box 1734, House 2436, Iqaluit, NU X0A 0H0. Ontario: Blakes Extra-Provincial Services Inc., Suite 4000, 199 Bay Street, Toronto, ON M5L 1A9. Prince Edward Island: Stewart McKelvey, 65 Grafton Street, Charlottetown, PE C1A 1K8. Québec: Services Blakes Québec Inc., 1 Place Ville Marie, Suite 3000, Montréal, QC H3B 4N8. Saskatchewan: MLT Aikins, 1500 Hill Centre I, 1874 Scarth Street, Whitehorse, YK Y1A 3T2.

In Brazi

The analyst or any close associates do not hold nor do they have any direct/indirect involvement in the acquisition, sale, or intermediation of the securities discussed herein. Any financial interests, not disclosed above, that the analyst or any close associates holds in the issuer discussed in the report is limited to investment funds that do not mainly invest in the issuer or industry discussed in the report and the management of which these persons cannot influence.